Cardiogenic Shock – SOLACI-SOCIME 2022@SCAI Session

✔️ Cardiogenic Shock – SOLACI-SOCIME 2022@SCAI Session

✔️ Video del SOLACI-SOCIME 2022

👨‍🏫 Contents:

00:15 – Interactive Case presentation: STEMI with Multivessel Disease and Cardiogenic Shock. Panel discussion Fellow from SOLACI – Dr. Daniel Zazueta (MEX)
10:03 – Classification and Prognosis: The SCAI SHOCK Consensus – Dr. Hector Tamez (USA)
21:42 – Treatment of STEMI with Cardiogenic Shock: PCI and MCS Selection and Timing – Dr. Mauricio Cohen (USA)
39:20 – Treatment Consideration in Women: Results from the RECOVER III Study – Dra. Alexandra Lansky (USA)
51:40 – Treatment of STEMI with Cardiogenic Shock: When to escalate to ECMO – Dr. Gregory Serrao (USA)


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Advances in Structural Intervention – SOLACI-SOCIME 2022

✔️ Advances in Structural Intervention - SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session 👨‍🏫 Content: 00:09 - Palabras de Bienvenida - Dr. Guering Eid-Lidt (MEX)...

Endovascular Treatment of Femoropopliteal Segment – SOLACI-SOCIME 2022

✔️ Endovascular Treatment of Femoropopliteal Segment - SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session 👨‍🏫 Content: 00:09 - How Palabras de bienvenida - Dr. Luis Virgen...

Pulmonary Valve – SOLACI-SOCIME 2022

✔️ Pulmonary Valve - SOLACI-SOCIME 2022 ✔️ SOLACI-SOCIME 2022 Scientific Sessions 👨‍🏫 Contents: 00:10 - How to select the type of THV in pulmonary valve...

Complex PCI: Distal Left Main Coronary Artery – SOLACI-SOCIME 2022

✔️ Complex PCI: Distal Left Main Coronary Artery - SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session.  👨‍🏫 Contents: 00:13 - Welcoming words - Dr. Álvaro...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...